On May 5, 2024, Johnson & Johnson Updated Results From Multi-Cohort Phase 1 Study Of The Safety And Efficacy; TAR-210 Results Show 90% Recurrence-Free Survival And 90% Complete Response In Patients With High-Risk And Intermediate-Risk Non-Muscle-Invasi…
Updated results reinforce the potential of TAR-210 to transform treatment of non–muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterationsSAN ANTONIO, May 5, 2024 /PRNewswire/ -- Johnson